Institute for International Research

Chairperson's Opening Remarks

Co-Chair: Philip T. Sager, MD, FACC, FAHA Executive Director, MSD/Global QT Strategy Leader, CV Research
ASTRAZENECA LP

Understanding How the Critical Path Initiative (CPI) Will Impact Phase I Trials

Christopher-Paul Milne, DVM, MPH, JD Assistant Director
TUFTS CENTER FOR THE STUDY OF DRUG DEVELOPMENT

Collaboration in the Industry: Taking a Closer Look at Wyeth's Translational Medicine Research Collaboration (TMRC)

Giora Feuerstein, MD, MSC, FAHA Assistant Vice President, Head of Discovery and Translational Medicine
WYETH RESEARCH

The Emerging Era of Biomarkers: Yesterday, Today and Tomorrow

Moderator:
Claudio Carini, MD, PhD, FRCPath, Vice President and Global Head of Translational Medicine
MDS PHARMA

Panelists:
Giora Feuerstein, MD, MSC, FAHA Assistant Vice President, Head of Discovery and Translational Medicine
WYETH RESEARCH

Judith Fox, PhD Senior Director of Research
CHIRON

Predictive Computer Simulation in Early-Stage Clinical Research

Sam Holtzman, PhD CEO
ROSA PHARMACEUTICALS

Breaking Free From the Mold-Examining Challenges and Innovation in Early Phase I Study Designs

Whaijen Soo, MD, PhD Senior Vice President, Medical Research
BIOGEN IDEC

Stephen Freestone, MD Medical Director
CHARLES RIVER LABORATORIES CLINICAL SERVICES

Regulatory Framework for Conducting Phase I Studies: a Comparison Between U.S., European Union and Canada

Mario Tanguay, PhD, B Pharm. Vice President, Scientific and Regulatory Affairs
ANAPHARM